A Pilot Comparison of 68Ga-P16-093 and 68Ga-PSMA-11 PETCT Imaging in Primary Prostate Cancer Patients

What this Trial Is About

Prostate cancer is a common cancer among men with high mortality rates. Detecting prostate tumors and metastases accurately is important but challenging with certain imaging methods like 18F-FDG PETCT. This research evaluates a new imaging agent called 68Ga-P16-093, which targets prostate-specific membrane antigen PSMA and aims to compare its diagnostic ability with the well-studied 68Ga-PSMA-11 in the same group of patients with primary prostate cancer. Participants receive two whole-body PETCT scans on consecutive days. Each scan involves an intravenous injection of either 68Ga-P16-093 or 68Ga-PSMA-11 at a dose of 1.8-2.2 MBq per kilogram of body weight. These radiopharmaceuticals are used to image prostate cancer lesions by targeting PSMA, which is overexpressed on prostate cancer cells. The study is a pilot comparison designed to assess and compare the performance of these two tracers. During the study, researchers measure the tumor detection rate and standardized uptake value SUV of tumors for up to one year. Participants undergo imaging procedures and provide informed consent before enrollment. The study monitors diagnostic accuracy and tracer uptake to evaluate the potential of the new agent. The total involvement includes PETCT scans on two separate days and follow-up assessments to review the imaging results.

68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients